Indian Pharma Industry Calls for Enhanced Support Amid USTR Special 301 Report Concerns

India’s pharmaceutical industry is seeking increased government support to bolster its formulations segment following its inclusion in the latest United States Trade Representative (USTR) Special 301 Report. The report highlights ongoing concerns about intellectual property rights protection and enforcement in India, especially within the pharmaceutical sector.

According to the Special 301 Report, India is among six countries identified for scrutiny due to perceived deficiencies in intellectual property rights enforcement. This has raised concerns among Indian pharma exporters about potential competitive challenges, particularly in the formulations market.

RS Goswami, founder and CEO of Hind Pharma, noted, “India manufactures the most affordable generic medicines. But now the pharma lobby in the US is trying to restrict imports. Indian manufacturers could face increased competition in the formulations segment.”

Despite these concerns, industry representatives emphasize that the likelihood of immediate regulatory action or legal repercussions remains low. Indian pharmaceutical companies maintain compliance with the World Trade Organization’s (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which limits the scope for legal disputes.

Jatish N Sheth, director at Srushti Pharma, explained, “The US itself provides significant patent protections domestically, so it would be incorrect to suggest that India’s approach is somehow wrong. As far as the USTR Special 301 Report is concerned, it is an ongoing process and largely reflects differing viewpoints under the TRIPS Agreement framework. There won’t be any material legal implications or a significant impact on India’s pharmaceutical exports.”

Exporters acknowledge that while the report may not trigger immediate regulatory changes, it could increase competitive pressures, especially for smaller Indian drugmakers that depend heavily on exports of low-cost generics.

Goswami further advocated for policy measures similar to those introduced for active pharmaceutical ingredients (APIs) to support the formulations segment. He stated, “There is also a need to simplify ease of doing business for the pharma sector.”

Industry stakeholders underline that India’s intellectual property framework aligns with international standards, having fully complied with the WTO’s TRIPS Agreement in 2005 by amending its Patent Act to introduce product patents.

Ramesh Juneja, chairman of Mankind Pharma, reinforced this position, saying, “There is no infringement by Indian pharma exporters. In 2005, India fully complied with the WTO’s TRIPS Agreement by amending its Patent Act to introduce product patents. A majority of pharma exports are WTO-compliant.” He added that India plays a critical role in supplying affordable essential medicines globally, including cancer treatments.

Nevertheless, concerns persist among smaller firms operating on thin margins. Some fear that heightened scrutiny or the imposition of non-tariff barriers could affect their access to the US market.

Despite these challenges, Indian pharmaceutical companies remain highly competitive in developing cost-effective medicines, contributing significantly to the global pharmaceutical supply chain.